Debates and reflection on modern proton radiotherapy and photon radiotherapy

Abstract

Abstract:

The debate on the merits of proton radiotherapy and photon radiotherapy has lasted for more than 20 years， mainly reflected in the comparison of dose distribution and clinical outcomes. Because dosimetric advantages do not always translate to better clinical outcomes， several phase Ⅲ comparative clinical studies are being conducted in Western countries. However， it is highly questionable that these studies will bring great value to the advancement of radiation therapy or settle the debate. This is because the effectiveness of the treatment depends not only on the type of radiation， but also on the technology used. Therefore， the focus of the research should not be which type of radiation is superior， but how to avoid its disadvantages while taking full advantage of the dose characteristics of each type of radiation. Both proton therapy and photon therapy will play an important role in cancer treatment in the future， and limited resources should be applied to maximize the effectiveness of each. With the rapid development of radiotherapy technology and systemic therapies including immunotherapy， reducing treatment fractions in the form of stereotactic radiosurgery and stereotactic body radiotherapy （SRS/SBRT） will be the inevitable trend. The need for dose focusing will drive photon therapy toward 4π radiotherapy using more non-coplanar fields， while higher geometric accuracy requirements will cause wide adoption of artificial intelligence-based online adaptive radiotherapy.

Key words:Proton therapy,Clinical study,Artificial intelligence,Photon radiotherapy,Dose focusing,Non-coplanar fields,Online adaptive radiotherapy

Yu Cedric, Ren Lei, Lu Xiaoguang. Debates and reflection on modern proton radiotherapy and photon radiotherapy[J]. Journal of International Oncology, 2024, 51(7): 411-416.

Figures/Tables1

References36

[1]	Mohan R. A review of proton therapy-current status and future directions[J].Precis Radiat Oncol,2022,6(2): 164-176. DOI:10.1002/pro6.1149.
[2]	Paganetti H, Yu CX, Orton CG. Photon radiotherapy has reached its limit in terms of catching up dosimetrically with proton therapy[J].Med Phys,2016,43(8): 4470. DOI:10.1118/1.4954790. pmid:27487862
[3]	Chen Z, Dominello MM, Joiner MC, et al. Proton versus photon radiation therapy: a clinical review[J].Front Oncol,2023,13: 1133909. DOI:10.3389/fonc.2023.1133909.
[4]	ClinicalTrials. gov.Showing results for: Cancer \| Other terms: photon proton phase Ⅲ \| radiation therapy \| Not yet recruiting, Recruiting studies[EB/OL]. [2024-06-10]. https://www.clinicaltrials.gov/search?cond=Cancer&term=photon%20proton%20phase%20iii&intr=radiation%20therapy&viewType=Table&limit=50&aggFilters=status:not%20rec.
[5]	Takagi M, Demizu Y, Fujii O, et al. Proton therapy for localized prostate cancer: long-term results from a single-center experience[J].Int J Radiat Oncol Biol Phys,2021,109(4): 964-974. DOI:10.1016/j.ijrobp.2020.11.007.
[6]	Wu YY, Fan KH. Proton therapy for prostate cancer: current state and future perspectives[J].Br J Radiol,2022,95(1131): 20210670. DOI:10.1259/bjr.20210670.
[7]	Corrao G, Marvaso G, Mastroleo F, et al. Photon vs proton hypofractionation in prostate cancer: a systematic review and meta-analysis[J].Radiother Oncol,2024,195: 110264. DOI:10.1016/j.radonc.2024.110264.
[8]	Goddard LC, Brodin NP, Bodner WR, et al. Comparing photon and proton-based hypofractionated SBRT for prostate cancer accounting for robustness and realistic treatment deliverability[J].Br J Radiol,2018,91(1028): 20180010. DOI:10.1259/bjr.20180010.
[9]	Yu JB, Destephano DM, Jeffers B, et al. Updated analysis of comparative toxicity of proton and photon radiation for prostate cancer[J].J Clin Oncol,2024,42(16): 1943-1952. DOI:10.1200/JCO.23.01604. pmid:38507655
[10]	Morris WJ, Tyldesley S, Rodda S, et al. Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer[J].Int J Radiat Oncol Biol Phys,2017,98(2): 275-285. DOI:10.1016/j.ijrobp.2016.11.026.
[11]	Galland-Girodet S, Pashtan I, MacDonald SM, et al. Long-term cosmetic outcomes and toxicities of proton beam therapy compared with photon-based 3-dimensional conformal accelerated partial-breast irradiation: a phase 1 trial[J].Int J Radiat Oncol Biol Phys,2014,90(3): 493-500. DOI:10.1016/j.ijrobp.2014.04.008.
[12]	Chowdhary M, Lee A, Gao S, et al. Is proton therapy a "Pro" for breast cancer? A comparison of proton vs. non-proton radiotherapy using the national cancer database[J].Front Oncol,2019,8: 678. DOI:10.3389/fonc.2018.00678.
[13]	DeCesaris CM, Rice SR, Bentzen SM, et al. Quantification of acute skin toxicities in patients with breast cancer undergoing adjuvant proton versus photon radiation therapy: a single institutional experience[J].Int J Radiat Oncol Biol Phys,2019,104(5): 1084-1090. DOI:10.1016/j.ijrobp.2019.04.015.
[14]	Bush DA, Do S, Lum S, et al. Partial breast radiation therapy with proton beam: 5-year results with cosmetic outcomes[J].Int J Radiat Oncol Biol Phys,2014,90(3): 501-505. DOI:10.1016/j.ijrobp.2014.05.1308.
[15]	Shah BA, Xiao J, Oh C, et al. Five-fraction prone accelerated partial breast irradiation: long-term oncologic, dosimetric, and cosmetic outcome[J].Pract Radiat Oncol,2022,12(2): 106-112. DOI:10.1016/j.prro.2021.08.009.
[16]	Lu HM, Flanz J.Characteristics of Clinical Proton Beams//Paganetti H. Proton therapy physics. 2rd ed[M]. Boca Raton: CRC Press. DOI:10.1201/b22053.2018: 113-135.
[17]	Paganetti H. Range uncertainties in proton therapy and the role of Monte Carlo simulations[J].Phys Med Biol,2012,57(11): R99-R117. DOI:10.1088/0031-9155/57/11/R99.
[18]	Schaffner B, Pedroni E. The precision of proton range calculations in proton radiotherapy treatment planning: experimental verification of the relation between CT-HU and proton stopping power[J].Phys Med Biol,1998,43(6): 1579-1592. DOI:10.1088/0031-9155/43/6/016. pmid:9651027
[19]	Klinker P, Visser S, Korevaar E, et al. OC-0787 Proton-based RT enables target dose escalation in oesophageal cancer with limited impact on OAR dose[J].Radiother Oncol,2023. DOI:10.1016/s0167-8140(23)08728-5.
[20]	Yu CX, Jaffray DA, Wong JW. The effects of intra-fraction organ motion on the delivery of dynamic intensity modulation[J].Phys Med Biol,1998,43(1): 91-104. DOI:10.1088/0031-9155/43/1/006. pmid:9483625
[21]	Belikhin M, Shemyakov A, Chernyaev A, et al. Dosimetric evaluation of target motion effects in spot-scanning proton therapy: a phantom study[J].Int J Part Ther,2024,11: 100013. DOI:10.1016/j.ijpt.2024.100013.
[22]	Decunha J, Newpower M, Vassiliev O, et al. O 06-Development and comparison of lineal energy spectrum-based and LETd-based proton-RBE models[J].Int J Part Ther,2024,11 Suppl: 100029. DOI:10.1016/j.ijpt.2024.100029.
[23]	Tran A, Zhang J, Woods K, et al. Treatment planning comparison of IMPT, VMAT and 4π radiotherapy for prostate cases[J].Radiat Oncol,2017,12(1): 10. DOI:10.1186/s13014-016-0761-0. pmid:28077128
[24]	杨涛, 徐寿平, 解传滨, 等. 前列腺癌质子调强与光子容积旋转调强放疗计划质量评估[J].中华放射医学与防护杂志,2020,40(1): 19-25. DOI:10.3760/cma.j.issn.0254-5098.2020.01.003.
[25]	Stuschke M, Kaiser A, Abu-Jawad J, et al. Re-irradiation of recurrent head and neck carcinomas: comparison of robust intensity modulated proton therapy treatment plans with helical tomotherapy[J].Radiat Oncol,2013,8: 93. DOI:10.1186/1748-717X-8-93. pmid:23601204
[26]	Kahalley LS, Ris MD, Grosshans DR, et al. Comparing intelligence quotient change after treatment with proton versus photon radiation therapy for pediatric brain tumors[J].J Clin Oncol,2016,34(10): 1043-1049. DOI:10.1200/JCO.2015.62.1383. pmid:26811522
[27]	Taghian AG, Kozak KR, Katz A, et al. Accelerated partial breast irradiation using proton beams: Initial dosimetric experience[J].Int J Radiat Oncol Biol Phys,2006,65(5): 1404-1410. DOI:10.1016/j.ijrobp.2006.03.017.
[28]	Verma V, Mishra MV, Mehta MP. A systematic review of the cost and cost-effectiveness studies of proton radiotherapy[J].Cancer,2016,122(10): 1483-1501. DOI:10.1002/cncr.29882. pmid:26828647
[29]	Aldenhoven L, Ramaekers B, Degens J, et al. Cost-effectiveness of proton radiotherapy versus photon radiotherapy for non-small cell lung cancer patients: exploring the model-based approach[J].Radiother Oncol,2023,183: 109417. DOI:10.1016/j.radonc.2022.11.006.
[30]	Underwood TS, Voog JC, Moteabbed M, et al. Hydrogel rectum-prostate spacers mitigate the uncertainties in proton relative biological effectiveness associated with anterior-oblique beams[J].Acta Oncol,2017,56(4): 575-581. DOI:10.1080/0284186X.2016.1275781. pmid:28075206
[31]	Brenner DJ, Martinez AA, Edmundson GK, et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue[J].Int J Radiat Oncol Biol Phys,2002,52: 6-13. DOI:10.1016/s0360-3016(01)02664-5.
[32]	Liu J, Park K, Shen Z, et al. Immunotherapy, targeted therapy, and their cross talks in hepatocellular carcinoma[J].Front Immunol,2023,14: 1285370. DOI:10.3389/fimmu.2023.1285370.
[33]	Rui R, Zhou L, He S. Cancer immunotherapies: advances and bottlenecks[J].Front Immunol,2023,14: 1212476. DOI:10.3389/fimmu.2023.1212476.
[34]	Dong P, Lee P, Ruan D, et al. 4π non-coplanar liver SBRT: a novel delivery technique[J].Int J Radiat Oncol Biol Phys,2013,85(5): 1360-1366. DOI:10.1016/j.ijrobp.2012.09.028.
[35]	Dong P, Lee P, Ruan D, et al. 4π noncoplanar stereotactic body radiation therapy for centrally located or larger lung tumors[J].Int J Radiat Oncol Biol Phys,2013,86(3): 407-413. DOI:10.1016/j.ijrobp.2013.02.002.
[36]	Rwigema JC, Nguyen D, Heron DE, et al. 4π noncoplanar stereotactic body radiation therapy for head-and-neck cancer: potential to improve tumor control and late toxicity[J].Int J Radiat Oncol Biol Phys,2015,91(2): 401-409. DOI:10.1016/j.ijrobp.2014.09.043.